Compare KMT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | BEAM |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | KMT | BEAM |
|---|---|---|
| Price | $29.31 | $27.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $25.83 | ★ $48.09 |
| AVG Volume (30 Days) | 809.0K | ★ 2.0M |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,982,871,000.00 | $55,701,000.00 |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $3.82 | $26.52 |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.30 | $13.53 |
| 52 Week High | $29.89 | $35.25 |
| Indicator | KMT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 57.59 |
| Support Level | $27.47 | $26.83 |
| Resistance Level | $29.89 | $28.28 |
| Average True Range (ATR) | 0.58 | 1.60 |
| MACD | 0.04 | 0.27 |
| Stochastic Oscillator | 74.45 | 63.54 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.